Thursday, October 15, 2026

Charter Comm, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Charter Comm, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Charter Comm, Inc.

7.5% sales growth and 10.64% return on equity

Charter Communications, Inc., through its subsidiaries, provides cable services to residential and commercial customers in the United States.

Charter Comm, Inc.'s sales growth this year is expected to be 5.8% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 48.1B for the twelve trailing months.

Charter Comm, Inc.'s sales growth for the next quarter is 7.5%. The company's growth estimates for the present quarter and the next is 127.4% and 26.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.64%.

Volatility

Charter Comm, Inc.'s last day, last week, and last month's current volatility was 0.32%, 0.43%, and 0.99%, respectively.

Charter Comm, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.50% (day), 1.75% (last week), and 2.35% (last month), respectively.

Charter Comm, Inc.'s Stock Yearly Top and Bottom Value

Charter Comm, Inc.'s stock is valued at $617.10 at 17:22 EST, below its 52-week high of $681.71 and way above its 52-week low of $449.83.

Charter Comm, Inc.'s Moving Average

Charter Comm, Inc.'s worth is under its 50-day moving average of $622.03 and under its 200-day moving average of $630.06.

3. BioDelivery Sciences International, Inc.

17.5% sales growth and 28.89% return on equity

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally.

BioDelivery Sciences International, Inc.'s sales growth this year is expected to be 13.7% and 21% for next year.

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 156.47M for the twelve trailing months.

BioDelivery Sciences International, Inc.'s sales growth for the next quarter is 17.5%. The company's growth estimates for the present quarter and the next is 40% and 600%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.89%.

Volatility

BioDelivery Sciences International, Inc.'s last day, last week, and last month's current volatility was 1.45%, 2.26%, and 2.73%, respectively.

BioDelivery Sciences International, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.78% (day), 4.11% (last week), and 4.96% (last month), respectively.

BioDelivery Sciences International, Inc.'s Stock Yearly Top and Bottom Value

BioDelivery Sciences International, Inc.'s stock is valued at $3.45 at 17:22 EST, way under its 52-week high of $5.45 and way above its 52-week low of $3.04.

BioDelivery Sciences International, Inc.'s Moving Average

BioDelivery Sciences International, Inc.'s worth is way under its 50-day moving average of $3.89 and way below its 200-day moving average of $3.96.

4. Coca Cola Femsa S.A.B. de C.V.

30.6% sales growth and 8.22% return on equity

Coca-Cola FEMSA, S.A.B. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages.

Coca Cola Femsa S.A.B. de C.V. 's sales growth this year is anticipated to be 10.7% and 3.7% for next year.

Year-on-year quarterly revenue growth declined by 6.7%, now sitting on 181.52B for the twelve trailing months.

Coca Cola Femsa S.A.B. de C.V. 's sales growth for the next quarter is 30.6%. The company's growth estimates for the present quarter and the next is 8.2% and 65.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.22%.

Volatility

Coca Cola Femsa S.A.B. de C.V. 's last day, last week, and last month's current volatility was 0.65%, 0.87%, and 0.94%, respectively.

Coca Cola Femsa S.A.B. de C.V. 's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.00% (day), 1.73% (last week), and 2.01% (last month), respectively.

Coca Cola Femsa S.A.B. de C.V. 's Stock Yearly Top and Bottom Value

Coca Cola Femsa S.A.B. de C.V. 's stock is valued at $47.84 at 17:22 EST, under its 52-week high of $49.16 and way higher than its 52-week low of $36.16.

Coca Cola Femsa S.A.B. de C.V. 's Moving Average

Coca Cola Femsa S.A.B. de C.V. 's worth is higher than its 50-day moving average of $46.29 and above its 200-day moving average of $44.65.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com